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Abstract
Introduction Optimal vitamin D status promotes skeletal
health and is recommended with specific treatment in indi-
viduals at high risk for fragility fractures. A growing body of
literature has provided indirect and some direct evidence for
possible extraskeletal vitamin D-related effects.
Purpose and Methods Members of the European Society
for Clinical and Economic Aspects of Osteoporosis and
Osteoarthritis have reviewed the main evidence for possible
proven benefits of vitamin D supplementation in adults at
risk of or with overt chronic extra-skeletal diseases, pro-
viding recommendations and guidelines for future studies in
this field.
Results and conclusions Robust mechanistic evidence is
available from in vitro studies and in vivo animal studies,
usually employing cholecalciferol, calcidiol or calcitriol in
pharmacologic rather than physiologic doses. Although
many cross-sectional and prospective association studies in
humans have shown that low 25-hydroxyvitamin D levels
(i.e., <50 nmol/L) are consistently associated with chronic
diseases, further strengthened by a dose-response relation-
ship, several meta-analyses of clinical trials have shown
contradictory results. Overall, large randomized controlled
trials with sufficient doses of vitamin D are missing, and
available small to moderate-size trials often included people
with baseline levels of serum 25-hydroxyvitamin D levels
>50 nmol/L, did not simultaneously assess multiple out-
comes, and did not report overall safety (e.g., falls). Thus,
no recommendations can be made to date for the use of
vitamin D supplementation in general, parental compounds,
or non-hypercalcemic vitamin D analogs in the prevention
and treatment of extra-skeletal chronic diseases. Moreover,
attainment of serum 25-hydroxyvitamin D levels well above
the threshold desired for bone health cannot be recom-
mended based on current evidence, since safety has yet to
be confirmed. Finally, the promising findings from
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mechanistic studies, large cohort studies, and small clinical
trials obtained for autoimmune diseases (including type 1
diabetes, multiple sclerosis, and systemic lupus erythema-
tosus), cardiovascular disorders, and overall reduction in
mortality require further confirmation.
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Introduction
Adequate vitamin D status is undoubtedly necessary for the
maintenance of optimal mineral and skeletal homeostasis, as
well as for the prevention and cure of secondary hyperpar-
athyroidism, rickets and osteomalacia [1]. The measurement of
serum levels of 25-hydroxyvitamin D [25(OH)D] is used both
to determine vitamin D status and to estimate the benefit of
vitamin D supplementation [2]. According to different guide-
lines, the thresholds for serum 25(OH)D have been set at 50 or
75 nmol/l (i.e., 20 or 30 ng/ml) for bone health [3–6]. Levels
of 25(OH)D beyond these thresholds do not appear to confer
additional benefits for mineral homeostasis [1, 7]. According
to international recommendations, vitamin D status has to be
determined in subjects at risk for disorders of bone and mineral
metabolism [3, 5]. Nonetheless, the wide availability of 25
(OH)D commercial assays has caused the requests for the
assessment of vitamin D status to increase markedly in recent
years and, according to the above-described thresholds, many
subjects have been defined as vitamin D deficient [8, 9].
Alternatively, current recommendations of the International
Osteoporosis Foundation with 600 IU per day in younger and
middle aged adults and 800 IU per day in older adults ensure
that over 97% of individual reach a replete vitamin D status
with 20(OH)D levels of 20 ng/ml [2, 10, 11]. Nonetheless,
while this mainly applies to the North American individuals, it
might not apply to populations that do not usually fortify their
foods with vitamin D thus displaying lower vitamin D levels
[2, 11].
Several reports have shown that vitamin D deficiency is
associated with an array of chronic diseases [12, 13]. Yet, the
causal effect of low serum levels of 25(OH)D on the onset and
progression of diseases that are unrelated to mineral home-
ostasis, has yet to be demonstrated in large clinical trials. Most
evidence is still based on observational studies [association
with ultraviolet B radiation (UVB) exposure, 25(OH)D levels]
[12, 13].
Large, randomized controlled clinical trials assessing the
benefits of sufficient dose of vitamin D supplementation on
different chronic diseases outside the skeleton as primary
endpoints are still lacking, and no specific thresholds have
been defined in this field for each different effect. Notably,
meta-analyses have limitations because of the selection of
studies, quality of endpoint assessment, analytical aspects
and interpretation of the results [14, 15]. Moreover, there is
still much uncertainty whether achieving values of serum 25
(OH)D greater than the recommended thresholds may lead
to any benefit in overall health [7, 16]. Nonetheless,
assessment of vitamin D status and vitamin D supple-
mentation are nowadays widely prescribed by different
specialists and general practitioners for a variety of chronic
conditions not classically linked to mineral and bone
metabolism abnormalities [17].
Members of the European Society for Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis, along
with experts in the field of vitamin D, convened a meeting
in February 2016 to broadly review the main evidence for
possible proven benefits of vitamin D supplementation in
adults at risk of or with overt chronic extra-skeletal diseases,
providing recommendations and guidelines for future stu-
dies in this field.
Therefore, the aims of this paper were: to summarize and
highlight the main available evidence of vitamin D-related
extraskeletal benefits, reviewed in detail elsewhere, mainly
ensuing from systematic reviews of large cohort data, small
randomized controlled trials (RCTs), and meta-analyses of
clinical trials; to give recommendations for clinical practice;
to issue the research agenda on the possible advantages of
vitamin D treatment on extra skeletal chronic diseases,
focusing on cardiovascular diseases and overall mortality,
diabetes mellitus, main autoimmune diseases, and cancer.
Molecular rationale (mechanistic data) for possible
extraskeletal vitamin D-mediated effects
The biologically active form of vitamin D, calcitriol [1,25
(OH)2D], is a multifunctional steroid hormone produced by
the kidney (Fig. 1). It exerts its actions through the acti-
vation of the vitamin D receptor (VDR), a nuclear receptor
almost ubiquitously expressed in most vertebrate cells, but
mostly present in the intestine, where it stimulates active
calcium absorption [5]. As demonstrated by in vitro and
in vivo evidence, calcitriol can also be synthesized in a
series of tissues in normal or pathologic conditions. Extra-
renal calcitriol mainly acts in an autocrine or paracrine
manner, in order to modulate functions not classically
related to mineral homeostasis. Whilst renal calcitriol pro-
duction is regulated by parathyroid hormone (PTH) and
fibroblast growth factor 23, two hormones that respectively
enhance or inhibit its production, the synthesis of extra-
renal calcitriol is driven by the bioavailable substrate, i.e.,
serum 25(OH)D. Concentrations of free or bioavailable 25
(OH)D in the local circulation at the target tissues are also
regulated by the levels of vitamin D binding protein
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(VDBP) [18]. The ubiquitous presence of the VDR and the
possible production of extra-renal calcitriol driven by the
concentration of the non-active pre-hormone, 25(OH)D,
constitute the physiological conditions for the potential
extra-skeletal effects of calcitriol and suggest a possible role
for parental vitamin D or 25(OH)D in maintaining or
enhancing these processes [19].
A recent RCT conducted in a small group of healthy
adults has demonstrated that any increase in vitamin D
levels would significantly affect the expression of genes
belonging to several pathways involved in the pathogenesis
of major chronic diseases [20].
Many in vitro studies have shown the effects of the
active hormone calcitriol on cells belonging to extra-
musculoskeletal tissues expressing both the VDR and
1alpha hydroxylase (1αOHase), the enzyme which ulti-
mately activates the pro-hormone 25(OH)D [21]. The
model of the VDR knockout mouse, which develops
hyperparathyroidism and rickets soon after weaning, has
reproduced in vivo the ligand dependent and independent
VDR-mediated effects also on organs not related to mineral
homeostasis, such as skin, cardiovascular/renin-angiotensin
system, and metabolic system [22, 23]. The global VDR
knockout mice also develop alopecia, hypertension,
Fig. 1 Vitamin D metabolism. Endogenous or exogenous cholecalci-
ferol and calcidiol are the inactive precursors of the biological active
hormone calcitriol. Calcitriol, classically produced in the kidneys under
the positive and negative regulation of parathyroid hormone (PTH) and
fibroblast growth factor 23 (FGF23), respectively, can also be
synthesized in extra-renal tissues, where its production is mainly driven
by the substrate, 25 hydroxyvitamin D (25(OH)D). The nearly ubi-
quitously expressed vitamin D receptor (VDR) mediates calcitriol
actions in skeletal and extra-skeletal tissues
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impaired insulin secretion, skeletal muscle fiber atrophy
with motor deficits, left ventricular hypertrophy and failure,
and cardiac fibrosis [22–28]. These mice are more prone to
skin cancer formation and impaired response to injury [29].
Many in vitro studies have shown the direct effects of
calcitriol in modulating the functions of cells belonging to
different human and animal tissues.
Vitamin D, cardiovascular diseases, and mortality:
evidence
The observations that both systolic and diastolic blood
pressure (SBP and DBP, respectively) increase with the
distance from the equator [30], and that seasonality for
major events such as hospitalizations and in-hospital death
and mortality in a large dataset [31], suggested that vitamin
D could play a role in modulating cardiovascular health and
mortality.
At a mechanistic level, several lines of evidence link
vitamin D to cardiovascular health. First, the VDR has been
found to be present in key tissues linked to cardiovascular
health, such as myocardial, endothelial, smooth muscle, and
pancreatic beta cells, as well as macrophages [32, 33].
Second, in situ production of the active hormone by the
1αOHase has been confirmed in all of the same tissues,
suggesting a requirement for calcitriol [32, 33]. Third, the
VDR knock-out mouse has been shown to suffer from
hypertension and congestive heart failure [22], further sup-
ported by the VDR mediated downregulation of the
expression of renin, which is one of the major determinants
in cardiovascular risk [34]. Forth, deletion of the VDR in
cardiomyocytes resulted in ventricular hypertrophy among
mice [25]. Finally, in humans, several large cohort studies
have demonstrated that low serum 25(OH)D levels are
predictive of an increased risk of incident hypertension [35,
36], myocardial infraction [37], and sudden cardiovascular
death [38, 39]. Notably, regarding a desirable 25(OH)D
range for optimal cardiovascular health, these large cohort
studies suggested that for incident hypertension in both men
and women, cardiovascular mortality and all-cause mortal-
ity, individual who had 25(OH)D levels between 50 and
130 nmol/l may have the lowest prospective risk [2]. In a
prospective cohort study of 3258 consecutive patients of
both genders and a mean age of 62 years scheduled for
coronary angiography, both all-cause and cardiovascular
mortality increased in a dose-dependent manner with
decreasing quartiles of baseline serum 25(OH)D levels [38].
In a prospective study of elderly men, low serum 25(OH)D
was associated with a substantial excess risk of death com-
pared to 25(OH)D values greater than 50–70 nmol/l [40].
Consistent findings come from the Longitudinal Study
Amsterdam where among 1317 senior men and women (age:
65–85 years) those with deficient serum 25(OH)D levels had
a significantly higher risk of overall mortality (HR 1.46;
95% CI 1.12–1.91 for 25(OH)D <25 nmol/l and HR 1.24;
95% CI 1.01–1.53 for 25(OH)D 25–49.9 nmol/l) [41].
Extending to peripheral artery disease, an inverse dose-
response relationship was observed cross-sectionally
between 25(OH)D status and peripheral arterial diseases
among individuals age 40 years and older in the large US
population-based NHANES III (2001–2004) study [42].
While a Mendelian randomization study has pointed to a
possible causal relationship between 25(OH)D levels and
hypertension by meta-analyzing data for up to 108,173
individuals from 35 studies [43], a similar study has failed
to confirm a causal relationship between serum 25(OH)D
levels and mortality rates [44].
Several RCTs, albeit small and short-term, have assessed
the effects of vitamin D supplementation on cardiovascular
parameters among vitamin D deficient individuals. In a group
including 18 subjects with hypertension, randomized to be
exposed to UVB or ultraviolet A radiation thrice weekly over
a period 6 weeks at suberythematous doses, both systolic
blood pressure (SBP) and diastolic blood pressure (DBP)
decreased by 6 mmHg in the UVB-treated group [45]. Fur-
thermore, a subsequent study, carried out on a group of 148
community-dwelling elderly women, demonstrated that the
administration of 800 IU of cholecalciferol (plus calcium)
led, in the short term (8 weeks), to a mean significant
decrease of 13 and 6mmHg in SBP and DBP, respectively,
being more effective than calcium alone [46]. In a pharma-
cokinetic study comparing calcidiol and cholecalciferol, 20
healthy postmenopausal women with low vitamin D status
(mean age 61.5 years) were randomized to receive 20mcg of
calcidiol or 20mcg (i.e. 800 IU) of cholecalciferol, leading to
a period of 4 months to mean serum 25(OH)D targets of 174
and 76 nmol/l, respectively. In the group of women receiving
calcidiol, blood pressure was significantly lower at each
measured time-point after the 1st week of treatment, with
sustained mean 5.7 mmHg decrease in SBP over 4 months of
treatment demonstrated in the group of women receiving
calcidiol vs. no change in the ones receiving cholecalciferol
(P= 0.002), independently of age, body mass index (BMI),
and baseline SBP [47].
In a short-term 8-week trial among 200 individuals with
hypertension and serum 25(OH)D levels less than 75 nmol/l
(mean 52.9 nmol/l) were randomized to receive 2800 IU of
cholecalciferol or placebo for 8 weeks [48] and vitamin D
treatment did not decrease blood pressure [48]. The authors
hypothesized that their null finding may have been due to
the fact that too many participants were not vitamin D
deficient at baseline. This is consistent with their post-hoc
subgroup analysis among participants who were vitamin D
deficient at baseline, who did have a significant benefit on
the renin-angiotensin system with vitamin D treatment
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group based on a reduction in their plasma aldosterone
concentration [49].
At the level of published meta-analyses of clinical trials
on the effect of vitamin D supplementation and blood
pressure, where blood pressure was measured as primary or
secondary end-point, or simply measured, a benefit of
vitamin D supplementation on blood pressure could not be
demonstrated [50–54]. The most recent meta-analysis
included 46 trials (total of 4541 participants) and sug-
gested a null effect of vitamin D on blood pressure, irre-
spective of subgroup [54].
At the level of published meta-analyses of clinical trials
on the effect of vitamin D supplementation and mortality,
the most recent Cochrane meta-analysis focused on all-
cause mortality and cancer mortality among 75,927 indi-
viduals from 38 studies on all-causes mortality and 44,492
individuals from 4 studies on cancer-mortality. This ana-
lysis showed a significant 6% reduction in all cause mor-
tality and a 12% reduction in cancer mortality in
supplemented subjects if compared with placebo or calcium
[55]. In a sequential meta-analysis taking into account
RCTs with vitamin D supplementation of any duration and
quality, the authors found a significant 4% reduction in all-
cause mortality [56]. In order to assess the effect on single
causes of mortality, another meta analysis including the
randomized evaluation of calcium or vitamin D (RECORD)
trial, and additional 21 RCTs among seniors, concluded that
vitamin D supplementation might protect against cardiac
failure in older individuals, but does not appear to protect
from stroke or myocardial infarction [57].
Desirable 25(OH)D levels for optimal risk reduction in
mortality have been explored in several epidemiologic
studies [38, 58–63], most of which suggested a continuous
inverse relationship between increasing values of 25(OH)D
and a lower risk of mortality. In some studies and reviews,
however, a U-shape or reverse J-shaped relationship has
been described with an increased risk of mortality both at
low and higher levels of 25(OH)D [60, 64–67].
In summary, evidence that link vitamin D to cardiovas-
cular health is limited to mechanistic studies, large cohort
studies and small clinical trials among vitamin D deficient
adults. Large clinical trials with a sufficient dose of vitamin
D, ideally tested among individuals at risk of vitamin D
deficiency, are missing for blood pressure, any major car-
diovascular events and mortality. Two ongoing trials are
addressing this gap with available results in 2018 [VITAL
Study [68], DO-HEALTH trial [69]. Both trials test 2000 IU
vitamin D against placebo with VITAL addressing major
cardiovascular events and DO-HEALTH blood pressure as
primary endpoints. Based on available data, effects are most
likely expected in deficient individuals and both trials have
undertaken recruitment strategies to target adults (VITAL:
age 50+; DO-HEALTH: age 70+) at risk of vitamin DTa
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deficiency, although they did not select for vitamin D
deficient subjects (i.e., serum 25(OH)D less than 20 ng/ml).
All ongoing large-scale multicenter clinical trials with pre-
defined cardiovascular endpoints are listed in Table 1.
Vitamin D, type II diabetes and obesity: evidence
Many studies have shown an association of type II diabetes
(T2D), metabolic syndrome and obesity with a poor vitamin
D status [70]. After the first observation that vitamin D
status itself affects pancreatic secretion of insulin after
proper stimulus in rats [71], further experimental studies
have demonstrated that pancreatic beta-cells express the
VDR and 1αOHase [70] and that calcitriol directly stimu-
lates insulin production by pancreatic islets [72], modulates
peripheral insulin sensitivity and systemic inflammation
in vitro and in vivo in animal models [70]. In humans, a
polymorphism of the VDR possibly impairing the response
to calcitriol has been shown to be a significant and positive
predictor of T2D and myocardial infarction [73].
In the NHANES III, serum 25(OH)D levels were
inversely correlated with the prevalence of T2D and mea-
sures of insulin resistance in a dose-dependent pattern in
some, but not in all, ethnic groups (i.e., non-Hispanic whites
and Mexican–Americans), without correlating with beta-
cell function [74]. In the large longitudinal study of the
Nurses Health Study, after adjustment for all the possible
co-variates, the risk of developing T2D was reduced by
33% in women with higher intake of vitamin D and calcium
(>1200 mg and >800 IU daily, respectively) [75]. As far as
the complications of diabetes are concerned, serum 25(OH)
D levels were shown to be an independent predictor of
macrovascular and microvascular problems in patients with
overt T2D [76].
A meta-analysis of longitudinal observation studies by
Song et al. included 21 studies with 76,000 participants and
calculated the risk of developing T2D according to baseline
vitamin D status [77]. The risk of developing T2D was
reduced by 38% in the subjects in the highest tertile for
serum 25(OH)D levels as compared with those in the lowest
tertile, with little heterogeneity among studies. The asso-
ciation was consistent regardless of various baseline vari-
ables, such as diagnostic criteria for diabetes, duration of
follow-up, or study size, and remained significant after
adjustment for BMI and intermediate biomarkers. A linear
trend analysis showed that a 4 ng/ml increment in 25(OH)D
levels corresponded to a 4% lower risk of developing T2D
[77]. Nonetheless, two Mendelian randomization studies
have failed to demonstrate a causal relationship between
a low vitamin D status and T2D or obesity, respectively
[78, 79]. Moreover, a systematic review and meta-analysis
has demonstrated that vitamin D and calcium supplements
had no effects on adiposity in adults [80]. The authors
concluded that the effort to increase 25(OH)D levels by
means of supplementation might not be beneficial to reduce
the risk of T2D or obesity [78–80].
The evidence from intervention trials assessing the
influence of vitamin D supplementation in T2D is still
scarce and mostly comprises post-hoc analyses. These
RCTs were mainly designed for non-glycemic outcomes,
they were often too short and the dose of administered
vitamin D was heterogeneous, as reported in a recent sys-
tematic review [81]. Whilst it appears that vitamin D sup-
plementation has a neutral effect on glycemic outcomes in
individuals with normal glucose tolerance and in people
with established T2D at baseline, its potential effect seems
to be more prominent in those people who are at increased
risk for diabetes [70].
RCTs specifically designed to assess the effect of vitamin
D supplementation on T2D risk and insulin sensitivity
(homeostatic model assessment of insulin resistance, i.e.,
HOMA) are still a few. In one of these studies performed in
healthy adults at increased risk for T2D with low vitamin D
status (≤55 nmol/l), only the subgroup of subjects with
prediabetes had an advantage from daily cholecalciferol,
administered at a dosage sufficient to target serum levels of
25(OH)D of >75 nmol/L in terms of increase in insulin
sensitivity [82].
In healthy adult individuals with low 25(OH)D levels,
supplementation with high dose vitamin D2 (50,000 IU/
week) had no effect increasing insulin secretion and insulin
sensitivity in the short-term (12 weeks) [83]. With respect to
at-risk subjects, in a recently published long-term RCT
involving 511 subjects (mean age 62 years) with prediabetes
within the Tromso cohort carried out in the years
2008–2015, 20,000 IU/week of cholecalciferol did not
prevent the progression to overt T2D [84].
Because of the potential adverse effects of high dose
vitamin D, one ongoing placebo-controlled study (ie. D2d
study) will test both the long-term safety and efficacy of
daily high-dose vitamin D supplementation (4000 IU/day)
on lowering the risk of progression to overt diabetes in
people with increased risk for this chronic disease [85].
In conclusion, no evidence exists, so far, that adminis-
tering vitamin D could reduce T2D or obesity in the general
population. The results obtained in subjects with pre-
diabetes require further confirmation by larger and longer
RCTs. Since higher doses are employed, studies on safety
are also needed.
Vitamin D and autoimmune diseases: evidence
Calcitriol is a regulator of the immune system [86, 87]. Whilst
it exerts stimulatory effects on innate immunity, which is
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aspecific and implicated in the defense against infections, it
also modulates the effectors of adaptive immunity, which is
acquired and antigen-specific [88]. The observations that the
geographic prevalence of autoimmune diseases such as mul-
tiple sclerosis (MS), type 1 diabetes mellitus (T1D), rheu-
matoid arthritis (RA) and other rheumatic diseases increases
with the distance from the equator or changes with season-
ality, as well as the worsening of these diseases in conditions
of low ultraviolet radiation (UV) exposure, have raised the
hypothesis that vitamin D could play a role in the patho-
genesis of these diseases [89–91]. Indeed, the transcriptomic
profile of the immune system in man varies with season and is
shifted towards a pro-inflammatory state in wintertime [92].
Nonetheless, the observation that UV irradiation can repress
the development of experimental autoimmune encephalo-
myelitis (EAE), a murine model of MS, independently of 25
(OH)D levels, has in part downsized the belief that UV could
act through vitamin D production to determine the above-
listed effects [93].
Calcitriol has been shown to modulate in vitro the
activity of key players of the immune system, such as
antigen presenting cells and T-lymphocytes [94]. Calcitriol
inhibits the type T1 helper cell function by suppressing
inflammatory cytokine production (IFN-γ and IL-2), IL-17
producing T-cells, and dendritic cell differentiation, whilst it
enhances the production of cytokines by the type T2 cells
(Th2) such as IL-10 and the activity of regulatory T (Treg)
cells [94]. In addition, calcitriol downregulates aromatase
expression and inflammatory cytokines in human macro-
phages [95]. These effects lead to an important defensive
mechanism against inflammation and improvement of tol-
erogenic phenotype. These findings, together with the fact
that individuals with autoimmune diseases often display a
poor vitamin D status as compared with controls, have led
to hypothesize a potential immunomodulatory effect for
vitamin D and to study the immune system in the VDR
knockout mouse model. Indeed, mice devoid of VDR failed
to demonstrate gross immune abnormalities, except for
impaired macrophage chemotaxis and a lower response to
anti-CD3 stimulation [26]. Moreover, vitamin D receptor
knockout mice were unexpectedly protected from low-dose
streptozotocin–induced diabetes mellitus and EAE was less
severe in VDR null mice [26, 96]. These immune defects
were rescued by means of a diet rich in calcium, lactose and
phosphate, demonstrating that they were an indirect effect
of VDR disruption and that, although calcitriol is a possible
pharmacologic or physiologic immunomodulator, these
actions are redundant in vivo [26]. Conversely, in animal
models of autoimmune disease, a benefit of the adminis-
tration of vitamin D, calcitriol or calcitriol analogs on pre-
venting the onset or blunting the disease progression via
direct modulation of immune cells (i.e., induction of tol-
erogenic dendritic cells) has been demonstrated [86, 97].
Epidemiological studies have shown an association
between serum 25(OH)D levels and the prevalence, inci-
dence, severity and progression of many autoimmune dis-
eases [88]. Indeed, higher levels of 25(OH)D have been
associated with a decrease in the likelihood of developing
autoimmune diseases such as MS, RA, T1D [98], especially
when taken early in life [86]. A systematic review and meta-
analysis has demonstrated that, despite heterogeneity, poor
vitamin D status was associated to an increased risk of
developing MS [99]. Moreover, two Mendelian randomi-
zation studies have recently pointed to a likely causal
relationship between poor vitamin D status and the risk of
MS [100, 101]. In MS, low vitamin D status has been
shown to be an independent early predictor of disease
activity and progression [102], in particular in patients
being treated with IFN beta-1b [103]. In addition, IFN beta
was indeed more effective in MS in the presence of high
levels of 25(OH)D [104].
The potential role of calcitriol as immunomodulator/
immune-suppressor gave rise to the hypothesis that calci-
triol or other active vitamin D analogs, such as alfa-calci-
diol, might be used as a pharmacologic agent to prevent
autoimmune disease in high-risk individuals, or to treat
overt autoimmune diseases and to protect transplanted
organs from rejections. However, calcitriol must be admi-
nistered in high doses to elicit an immunomodulatory effect
and suppress proinflammatory cytokines. For this reason, it
cannot be used in humans. Non-hypercalcemic analogs of
calcitriol are currently under investigation.
The fact that calcitriol can be synthesized by immune cells
because of the expression of 1αOHase, which is regulated by
its substrate, i.e., 25(OH)D, has been exploited to support the
concept that vitamin D supplementation with parental vita-
min D compounds could be considered for the pharmaco-
logic adjuvant treatment of autoimmune diseases [21].
A few RCTs have demonstrated that supplementation
with the pro-hormone vitamin D has similar effects with
respect to calcitriol on cell-mediated immunity. Indeed,
monthly supplementation with high dose (140,000 IU)
vitamin D3 increased significantly peripheral regulatory T-
cells in adult healthy donors in the short term of 3 months,
as compared to placebo [105]. Similarly, daily high dose
vitamin D3 (4000 IU daily) led to a significant decrease in
CD4 cytotoxic T-cell activation compared to low dose
vitamin D3 (400 IU/day) [106].
In patients relapsing-remitting MS (RRMS, study group
94 subjects) high dose vitamin D intake (50,000 IU every 5
days for 3 months) along with IFN-β treatment led to a
significant increase in mental quality of life vs. placebo
[107]. An even higher dose of cholecalciferol (10,400 IU/
day) was proven to be safe and well tolerated, at least in the
short-term (6 months), and led to pleiotropic immunomo-
dulatory effects (decreased production of IL-17 and
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proportion of effector memory CD4+ cells), with a con-
comitant increase in central memory CD4+ cells [108].
These latter findings confirm previous results obtained in
similar randomized controlled studies in MS (as reviewed in
110). However, larger and long-term studies are necessary
to confirm the efficacy and safety of vitamin D supple-
mentation in MS [109].
Vitamin D supplementation early in life (2000 IU daily)
has been shown to reduce the risk of developing T1D in at-
risk subjects in a retrospective study in northern Finland,
where individuals are likely to be vitamin D deficient for
most part of the year [110]. A recent study in mice indicated
that high dose parental vitamin D3 reduced the incidence of
diabetes in a mouse model, which spontaneously develops
diabetes (non-obese diabetic, i.e., NOD mouse), when the
vitamin was administered at high doses and lifelong from 3
weeks of age [111]. Randomized controlled longitudinal
studies are ongoing to assess this effect of vitamin D in at-
risk human young populations. As far as the early stages of
disease are concerned, both alfacalcidiol and parental vita-
min D3 (70 IU/Kg body weight/day) have been proven to
be effective on residual beta-cell function in latent auto-
immune diabetes in adults and improved suppressor func-
tion of regulatory T cells in patients with T1D, respectively,
in recently published RCTs [112, 113]. Data on larger
groups of individuals confirming these results are still
missing in T1D.
The demonstration of circannual rhythms in RA and
systemic lupus erythematous (SLE) and the lower risk of
developing RA in the case of higher UVB exposure, suggest
that a possible association with vitamin D status might exist
[114–116]. However, a post-hoc analysis of the Women
Health Initiative study failed to show an association
between RA and solar irradiation, and suggested an
increased incidence of RA with higher vitamin D exposure
of just 440 IU/day vs. placebo [117]. Contradictory results
arose from meta-analyses assessing the association between
vitamin D intake and risk of RA and SLE in women [118,
119], whereas a recent meta-analysis, including 24 cross-
sectional studies and involving 3489 subjects, showed a
negative association between 25(OH)D levels and disease
activity in subjects with RA [120]. Thus far, no RCTs have
been carried out to definitively demonstrate a causal rela-
tionship between RA and vitamin D status by assessing the
effects of vitamin D supplementation on the course of the
disease. In SLE, a RCTs comparing the effect of daily
supplementation with 2000 IU cholecalciferol against pla-
cebo in patients with active disease demonstrated that daily
supplementation with cholecalciferol administered over a
period of 1 year led to a significant improvement in disease
activity, along with a significant decrease in inflammatory
markers [121]. Unfortunately, these results have not been
confirmed in a crossover trial with a 2-year duration, in
which 32 women with SLE were randomized to different
regimens of cholecalciferol (25,000 IU monthly or 300,000
IU initial bolus followed by 50,000 IU monthly). The higher
dose was not effective in modulating disease activity,
despite an increase in the number of Treg cells [122, 123].
A recent Cochrane meta-analysis has shown that there is
insufficient evidence to consider vitamin D as a possible
relief for several conditions characterized by chronic pain
[124].
Although the effects of calcitriol on the modulation of
the immune system in vitro are consistent, it remains to be
clarified whether these effects have been observed because
of the higher pharmacologic doses administered in culture
and whether they can be reproduced in vivo. Many of these
effects seem to arise directly from the VDR-mediated
actions of calcitriol, as demonstrated in animal models.
While the in vivo administration of active vitamin D at high
doses is not possible because of the hypercalcemic effects, it
is not clear to what extent a supplementation of parental
vitamin D compounds (cholecalciferol and calcidiol) or
non-hypercalcemic calcitriol analogs, could lead to a mod-
ulation of the immune system, taking advantage of the
possible induction of 1αOHase present in the immune cells.
Promising results have recently been obtained in indi-
viduals with MS and subjects at high risk for T1D with
vitamin D deficiency by means of larger doses of parental
compounds (D3) or active vitamin D analogs. However,
larger long-term RCTs assessing safety along with efficacy
are needed. The evidence for potential benefits in rheumatic
autoimmune diseases is still lacking and requires RCTs
possibly carried out during the early stages of the disease to
control progression, and in later stages for the prevention of
flare-ups.
Vitamin D and cancer: evidence
Calcitriol controls cellular proliferation and differentiation
in vitro. Calcitriol induces apoptosis, autophagy and growth
arrest of cancer cells or their progenitors, enhances DNA
repair and antioxidant protection, and modulates the immune
system to react against cancer [125]. Thus, active vitamin D
may inhibit cancer progression and metastasis [125]. These
effects are mediated by the VDR, which is expressed by
tumor cells along with 1αOHase. This, in turn, is responsible
for the local conversion of the pro-hormone 25(OH)D into
the biologically active vitamin D. Unfortunately, the capa-
city to hydroxylate the direct precursor of active vitamin D is
progressively lost by cancer cells, especially in prostate
cancer [125]. Mice devoid of the VDR were more prone to
skin cancer in response to chemical carcinogens or UVB
irradiation, although they did not spontaneously develop
tumors [126]. In a murine model of bone metastasis, vitamin
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D deficiency favoured the growth of injected prostate cancer
cells in bone likely changing the bone microenvironment
[127]. In this regard, it has been also argued that calcitriol
could play a role in modulation of osteoblasts, osteoclasts
and quiescent cancer cells within the pre-metastatic niche in
bone and possibly prevent bone metastases [128].
In humans, epidemiological data have shown an
increased prevalence of several types of cancer in the
northern areas of the northern hemisphere, suggesting an
inverse trend with the amount of UV exposure [129]. Many
studies have shown an increased prevalence of vitamin D
deficiency in individuals with cancer vs. controls and an
association between low vitamin D status and increased risk
of developing various tumors, such as breast, prostate, and
colon cancer, as well as disease severity [129–132]. Thus, it
was suggested that higher serum levels of 25(OH)D and, for
prostate cancer, higher serum levels of 1,25(OH)2D, would
inhibit colorectal, breast and prostate carcinogenesis
[130–133]. In particular, levels of 25(OH)D far above the
thresholds generally advised for the maintenance of bone
and mineral homeostasis (i.e., >50 ng/ml) would prevent
cancer. Based on these observational data, it was estimated
that even modest increase in serum 25(OH)D levels to
40–60 ng/ml would have prevented 58,000 new cases of
breast cancer and 49,000 new cases of colon cancer in the
United States and Canada each year, with correspondent
reduction in cancer-related mortality rates [134]. Surpris-
ingly, a recent pooled analysis demonstrated an increased
risk of prostate cancer along with higher vitamin D intake
[135], further confirming that no definitive conclusions can
be drawn by observational studies in this field.
Meta-analyses have assessed the association between
VDR polymorphisms and cancers, showing that variants of
the VDR or higher levels of VDBP were associated with an
increased risk for certain types of cancer [136, 137]. These
results suggest that, besides 25(OH)D levels, the VDR-
mediated response to active vitamin D or the VDBP-
regulated exposure to active vitamin D could also be
associated with the risk and progression of cancer, and
could be considered additional variables in determining the
vitamin D-related cancer risk and progression of cancer.
Early studies examined the risk of cancer by means of
secondary analyses of previous RCTs, including the Women
Health Initiative, and reported no significant cancer risk
reduction in individuals supplemented with vitamin D [138].
Some RCTs have been carried out to specifically assess
whether vitamin D supplementation can indeed prevent
cancer. A group of 1179 community-dwelling women was
randomized to receive 1400–1500 mg supplemental calcium
plus 1100 IU/day vitamin D3, calcium alone or placebo, and
followed-up for a 4-year period. In the intention-to-treat
analysis, the supplementation of vitamin D and calcium was
shown to be effective in reducing all-cancer risk, with a
cancer-free survival 77% higher in the calcium-vitamin D
group vs. placebo [139].
A meta-analysis took into account RCTs, prospective
cohort studies and nested case–control studies mainly per-
formed in older women, with data on risk of cancer and
cancer-related mortality (three studies), or fracture out-
comes (16 studies) [140], It was shown that, whilst com-
bined calcium and vitamin D supplementation (1000 IU/
day) may reduce the risk for all cancers, with a
dose–response relationship observed for colon cancer but
not for breast and prostate cancer, surprisingly, higher
concentrations of serum 25(OH)D were associated with
increased cancer risk [140]. A Cochrane meta-analysis
included a total of 50,623 participants, healthy or diagnosed
with a specific disease, from 18 RCTs trials, which com-
pared the effect of vitamin D supplementation/treatment
(cholecalciferol, ergocalciferol, calcitriol, or alfacalcidiol, at
any dose or regimen) vs. placebo on the risk of cancer. No
conclusion could be drawn in terms of cancer prevention
[141]. In a recently published, well-designed, multicenter,
US-based RCT, 2259 subjects surgically treated for color-
ectal adenomas were randomized to receive daily vitamin
D3 (1000 IU), calcium as carbonate (1200 mg), both or
neither [142]. It was demonstrated that daily supplementa-
tion with vitamin D3, calcium, or both were ineffective in
modifying the rate of recurrencies of colorectal adenomas
over a period of 3–5 years [142].
As far as cancer mortality is concerned, there are con-
flicting results whether vitamin D supplementation reduces
cancer-related mortality have been found [143, 144].
Although some evidence points to a possible role of
treatment with active vitamin D analogs specifically in
prostate cancer, the results of clinical studies are still
underpowered and inconclusive, and require additional
well-designed trials to establish efficacy [133, 145].
Secondary hyperparathyroidism is independently asso-
ciated with poor prognosis in prostate cancer patients,
especially when undergoing antiresorptive treatment for
bone metastases [128, 146]. For this reason, in patients with
metastatic bone disease, in whom treatment with agents
such as bisphosphonates (i.e., zoledronic acid) or denosu-
mab is commenced, vitamin D supplementation is recom-
mended in order to normalize serum PTH levels and prevent
side effects such as antiresorptive-induced hypocalcemia
[146, 147].
In conclusion, although there is a high prevalence of low
levels of vitamin D in cancer patients, insufficient evidence
exists on the likely reduction of cancer incidence and
mortality by vitamin D. The results of ongoing RCTs will
possibly clarify these issues, in particular the optimal
plasma concentrations of 25(OH)D to be achieved to get an
effect for cancer prevention and/or treatment. In patients
with prostate cancer undergoing antiresoptive therapy for
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the treatment of bone metastases, vitamin D supplementation
should be undertaken to normalize serum PTH levels and
decrease the risk of antiresorptive-related hypocalcemia. A
similar recommendation may apply to patients with breast
cancer commencing an antiresorptive therapy for prevention
or treatment of bone metastases [148]. The efficacy and
safety of active vitamin D analogs in certain types of cancer
(i.e., prostate cancer) should be further explored.
Vitamin D and chronic diseases in adults:
considerations, recommendations and research
agenda
In the vitamin D field, the strong mechanistic evidence for
extra skeletal outcomes mainly ensues from in vitro studies,
usually employing calcitriol in pharmacologic rather than
physiologic doses, and from association studies, showing
that low 25(OH)D levels (i.e., <50 nmol/l) are consistently
associated with chronic diseases in prospective cohort stu-
dies with a dose–response relationship. Indirect evidence
arises also from studies showing a direct trend between
pathologic parameters or diseases, such as cardiovascular
disorders, cancer, or autoimmune conditions, and the dis-
tance from the equator as well as fluctuations with sea-
sonality (i.e., according to sub-optimal UV exposure).
Many cross-sectional studies have investigated the
association between serum 25(OH)D levels and various
parameters in health and disease. Although these studies
have linked hypovitaminosis D to numerous disorders
affecting different systems such as the cardiovascular,
immune, endocrine/metabolic systems, they have not yet
Fig. 2 Calcitriol-mediated extraskeletal effects, as demonstrated
in vitro and in vivo in animal models, likely mediating the possible
extraskeletal effects in chronic diseases in humans (Asterisk shown
according to Evidence Based Medicine’s levels 1b–2b; ND not
demonstrated, i.e. level of evidence 2c and below). The extraskeletal
effects have to be further confirmed given contradictory results in
meta-analyses and randomized controlled trials (RCT)
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proven a causal relationship between a suboptimal vitamin
D status and the onset and progression of these diseases.
The Mendelian randomization method can be used in this
setting, by using gene variants (i.e., polymorphisms) to
make causal inferences in epidemiology and assess the
causal effect of the exposure to different levels of serum 25
(OH) on disease in non–experimental studies [149]. This
method has been recently exploited in the vitamin D field
to further assess the results of cross-sectional or long-
itudinal studies in large cohorts of subjects, where blood
samples for genetic studies were available [149].
These observations are still not supported by gross evi-
dence in chronic diseases in humans, as demonstrated by
the few available RCTs and the many meta-analyses and
systematic reviews, often showing contradictory results
(Fig. 2). Moreover, ecological evidence of the association
between the prevalence of chronic diseases and UV irra-
diation arises from studies performed in the northern
hemisphere, while these results are not reproduced in the
southern hemisphere. There is definitely a preponderance of
association studies over studies to demonstrate causality.
RCTs employing parental vitamin D compounds (cho-
lecalciferol or calcidiol) in small cohorts of subjects have
shown some results, yet far from leading to recommending
for vitamin D use for primary or secondary prevention of
extraskeletal diseases. Overall, the available RCTs analyz-
ing the effect of vitamin D supplementation on specific
extraskeletal outcomes is still scarce and clinical benefits
from large RCTs of supplementation with vitamin D com-
pounds, assessing both multiple outcomes and safety, have
yet to be reported. The inclusion of participants with
baseline serum 25(OH)D above the upper limit of defi-
ciency (i.e., 50 nmol/l) could attenuate the effect of vitamin
D on the main extraskeletal outcomes. Moreover, when
employing large doses of vitamin D, safety has not usually
been assessed. Monthly doses of vitamin D (or vitamin D
supplements administered at even longer intervals) have
been considered safe as far as classic side effects (i.e.,
hypercalciuria and hypercalcemia) are concerned and
because of the long half-life of vitamin D. Nonetheless, this
concept may have to be revised both because the half-life of
vitamin D can be modulated by VDBP and because other
active vitamin D-related metabolites can be produced dur-
ing supplementation possibly modulating the main out-
comes and/or mediating non-classic, adverse effects such as
falls [7, 150–152]. These issues have not been taken into
consideration in the trials assessing the effect of large doses
of vitamin D in MS or in individuals at high risk of
developing T1D.
Systematic reviews including large cohorts of patients
belonging to cross-sectional or longitudinal studies or to
meta-analyses of randomized intervention studies have
shown an association with vitamin D status as measured by
baseline or attained serum 25(OH)D levels and disease
onset and progression in several contexts. One of the major
concerns is represented by the U-curve relationship
demonstrated by some of these studies, i.e., an increased
risk both for low and high levels of serum 25(OH)D and
disease or mortality. The lack of standardization of serum
vitamin D assays [153], and the fact that meta analyses
often combine trials including subjects with different start-
ing baseline levels of serum 25(OH)D and employing dif-
ferent regimens of vitamin D to reach the same 25(OH)D
target levels, are the major limitations of these studies.
Indeed, the same attained level of serum 25(OH)D can be
obtained after administering large doses at large intervals of
time (bolus doses determining peak levels may be linked to
unwanted effects, such as falls) or small doses, administered
daily or weekly. Moreover, none of these studies take into
account the possible production of active metabolites with
short half-life, other than 25(OH)D or 1,25(OH)2D, which
could contribute to the efficacy and safety profile of vitamin
D supplementation [151].
For all the above reasons, it is still not possible to
recommend the use or a dosage of vitamin D or related
compounds as well as targets for serum 25(OH)D levels for
the prevention or treatment or chronic, extra skeletal dis-
eases, such as cardiovascular disorders, diabetes, auto-
immune diseases, cancer and mortality. Nonetheless,
supplementation with vitamin D along with antiresorptive
therapy administered for the prevention of skeletal-related
events or to treat bone metastases is needed, to control
secondary hyperparathyroidism and prevent hypocalcemia.
Further studies are needed in this field (Table 2).
It is advisable to perform large RCTs with multiple
outcomes, assigning participants of similar age to different
regimens of vitamin D supplementation, also comparing
Table 2 Vitamin D and extraskeletal effects: research agenda
• To perform large randomized controlled trials simultaneously
assessing multiple outcomes, assessing the efficacy of parental
vitamin D compounds (cholecalciferol, ergocalciferol, calcidiol) or
non-hypercalcemic active vitamin D analogs
• To employ and assess the efficacy of multiple regimens of parental
vitamin D compounds
• To measure baseline and attained serum 25(OH)D levels by mass
spectrometry, also in order to assess serum levels of other active and
non-active intermediate/final vitamin D metabolites
• To enroll subjects with baseline serum 25(OH)D levels lower than
20 ng/ml (50 nmol/l)
• To assess safety in clinical trials evaluating non classical toxic
effects (i.e. falls), besides classical toxic effects (hypercalciuria and
hypercalcemia)
• To perform meta-analyses pulling together RCTs employing the
same regimen, the same age group, and individuals with comparable
baseline 25(OH)D levels
• To publish negative results of RCTs
Endocrine (2017) 56:245–261 255
pro-hormones besides cholecalciferol, such as ergocalci-
ferol (vitamin D2) and calcidiol [25(OH)D], which are
supposed to give rise to different active intermediate
metabolites with short half-life after supplementation that
could be responsible for wanted or unwanted biologic
effects. Levels of baseline and attained serum 25(OH)D
should be measured with standard assays (i.e., mass spec-
trometry). Participants with low vitamin D levels (i.e., <50
nmol/l) should be enrolled. Safety (number of falls) should
always be assessed as a secondary outcome. Studies
employing multiple regimens of vitamin D, possibly against
placebo, should be planned in order to test whether a
dose–response relationship exists.
Furthermore, it is necessary to perform meta-analyses
pulling together RCTs employing the same regimen, the same
age group, and not just the target attained serum 25(OH)D,
and individuals with comparable baseline 25(OH)D levels.
Negative trials should be published and included in meta-
analyses.
While the administration of calcitriol should be avoided
for the high risk of hypercalciuria and hypercalcemia, RCTs
employing active, non-hypercalcemic vitamin D analogs
should be carried out in patients with specific tumors, such
as prostate cancer.
Conclusion
The promising results from the growing literature on the
associations between vitamin D and extraskeletal chronic is
not matched by the results obtained in intervention studies.
To prove a causal relationship and recommend the use of
vitamin D-related compounds in extra skeletal diseases,
more trials are needed to demonstrate that maintaining 25
(OH)D levels within a certain range may be useful and safe
in both the prevention and treatment of these diseases.
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